| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 327,20 | 328,00 | 21:17 | |
| 326,95 | 328,25 | 21:17 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 349,00 | 10 | |||
| 339,10 | 6 | |||
| 339,00 | 6 | |||
| 338,90 | 10 | |||
| 338,10 | 1 | |||
| 328,40 | 26 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/amg.htm [/URL] | ||||
| 26 | 327,35 | |||
| 10 | 316,80 | |||
| 6 | 316,70 | |||
| 6 | 316,60 | |||
| 1.053 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.101 | 0,054 | 59 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:42 | 329,20 | 60 |
| 17:02:42 | 332,00 | 1 |
| 15:47:10 | 333,00 | 4 |
| 15:46:37 | 332,80 | 20 |
| 15:39:43 | 331,25 | 19 |
| 15:39:33 | 331,25 | 1 |
| 15:35:00 | 330,45 | 10 |
| 15:35:00 | 330,45 | 20 |
| 15:30:04 | 331,65 | 53 |
| 15:30:02 | 331,70 | 11 |
| 14:54:40 | 329,80 | 4 |
| 14:54:40 | 329,80 | 34 |
| 12:34:51 | 330,00 | 18 |
| 12:34:51 | 330,00 | 51 |
| 12:34:51 | 330,00 | 31 |
| 12:34:51 | 329,90 | 7 |
| 12:31:00 | 329,95 | 4 |
| 12:31:00 | 329,60 | 6 |
| 12:12:36 | 328,55 | 9 |
| 10:55:44 | 329,25 | 23 |
| Tagesumsatz Xetra | +9,80 +3,07 % | 546 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19:12 | AAPL, AA, BKR, and AMGN are among the top stocks for momentum, says Oppenheimer | 10 | Seeking Alpha | ||
| Mi | Is Amgen Stock Outperforming the Dow? | 13 | Barchart.com | ||
| Di | NSE - AMGEN INC - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 4 | SEC Filings | ||
| 23.02. | If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today | 7 | Benzinga.com | ||
| AMGEN Aktie jetzt für 0€ handeln | |||||
| 20.02. | The Analyst Verdict: Amgen In The Eyes Of 18 Experts | 20 | Benzinga.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:06 | UroGen Pharma Ltd.: UroGen Announces ZUSDURI Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results | GlobeNewswire (Europe) | Commercial launch is on-track for ZUSDURI, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales... ► Artikel lesen | |
| 14:38 | Ainos, Inc.: Ainos Issues Shareholder Letter on Phased AI Nose Deployment of Up to 20,000 Systems and Scalable Recurring Revenue Opportunity | ACCESS Newswire | HOUSTON, TEXAS / ACCESS Newswire / March 2, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today issued the following letter from Chairman, President and Chief Executive Officer... ► Artikel lesen | |
| 14:00 | UroGen Pharma Ltd.: UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors | GlobeNewswire (Europe) | Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125... ► Artikel lesen | |
| 14:50 | Moderna freut sich über eine Zulassungsempfehlung der EMA für einen Kombi-Impfstoff gegen Corona und Grippe | NTG24.de | Bei Corona-Impfstoffen war der US-Konzern Moderna noch ein Nachzügler. Anders scheint es nun bei Kombi-Impfstoffen zu laufen, die gleichzeitig vor Corona und der Grippe schützen. Dafür gibt es bisher... ► Artikel lesen | |
| 16:57 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen |